Benefit of prompt initiation of single-inhaler fluticasone furoate, umeclidinium, and vilanterol (FF/UMEC/VI) in patients with COPD in England following an exacerbation: a retrospective cohort study

Abstract Background Triple therapy is recommended for patients with chronic obstructive pulmonary disease (COPD) who remain symptomatic despite dual therapy. The optimal timing of triple therapy following an exacerbation of COPD is unknown. The outcomes of prompt (≤ 30 days) vs. delayed (31–180 days...

詳細記述

書誌詳細

主要な著者:	Afisi S. Ismaila, Kieran J. Rothnie, Robert P. Wood, Victoria L. Banks, Lucinda J. Camidge, Alexandrosz Czira, Chris Compton, Raj Sharma, Shannon N. Millard, Olivia Massey, David M. G. Halpin
フォーマット:	Artigo
言語:	Inglês
出版事項:	BMC 2023-09-01
シリーズ:	Respiratory Research
主題:	Chronic obstructive pulmonary disease Exacerbation FF/UMEC/VI Healthcare cost SITT
オンライン･アクセス:	https://doi.org/10.1186/s12931-023-02523-1
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!